HANSOH PHARMA(HK:03692) 生物世界·2026-03-06 04:31Core Viewpoint - Lung cancer is the most common malignant tumor globally, accounting for approximately 18.7% of all cancer-related deaths. The article discusses the potential of B7-H3-targeted antibody-drug conjugates (ADCs) in treating lung cancer, particularly focusing on the drug HS-20093 developed by Hansoh Pharmaceutical, which has shown promising results in clinical trials [2][5]. Group 1: Drug Development and Mechanism - HS-20093 is an ADC targeting B7-H3, utilizing a cleavable linker to couple a fully human monoclonal antibody with a topoisomerase I inhibitor, achieving an average drug-antibody ratio (DAR) of 4 [5]. - B7-H3 is highly expressed in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), making it an ideal target for ADC development [2]. Group 2: Clinical Trial Results - The ARTEMIS-001 trial evaluated HS-20093 in 306 previously treated patients with advanced solid tumors, determining a maximum tolerated dose of 12.0 mg/kg in phase 1a [6]. - Among 236 lung cancer patients receiving doses of 8.0 or 10.0 mg/kg, the confirmed objective response rate was 52.3% for extensive-stage SCLC (N = 65) and 22.4% for NSCLC (N = 152) [6]. - The most common treatment-related adverse events included neutropenia (25.5% vs 50.5%), leukopenia (19.7% vs 42.4%), and anemia (16.8% vs 34.3%) [6]. Group 3: Safety and Efficacy - HS-20093 demonstrated good antitumor activity in lung cancer patients, with a low serum exposure of the effective payload indicating high stability in vivo [12]. - The safety profile of HS-20093 was controllable, with treatment-related interstitial lung disease and fatal adverse events occurring at rates of 3.4% and 3.8%, respectively [6].